GWM
CMRX

Geneos Wealth Management’s Chimerix, Inc. CMRX Stock Holding History

Geneos Wealth Management’s Portfolio CMRX Stock Details CMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,691
Closed -$16K – 3157
2020
Q4 		$16K Buy
+1,691
New +$6.13K ﹤0.01% 2042

Other funds holding CMRX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geneos Wealth Management's CMRX Position: Q1 2021 in Review

Geneos Wealth Management sold out of Chimerix, Inc. (CMRX) in Q1 2021, closing a stake of 1,691 shares — an estimated $16K sold.

Geneos Wealth Management first reported a position in CMRX in Q4 2020 and held it in 1 quarter. The position peaked at $16K in Q4 2020. 99 funds tracked by Wall St. Rank hold CMRX as of Q1 2021.

  • Geneos Wealth Management reported no remaining Chimerix, Inc. position as of Q1 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 1,691 Chimerix, Inc. shares in Q1 2021, an estimated $16K.
  • Geneos Wealth Management first reported a position in Chimerix, Inc. in Q4 2020 and held it in 1 quarter.
  • Geneos Wealth Management's Chimerix, Inc. position peaked at $16K in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Chimerix, Inc. as of Q1 2021.

Based on Geneos Wealth Management's 13F filing for Q1 2021, filed 17 Jun 2021.